Last reviewed · How we verify
corneal debridement of corneal abrasion
corneal debridement of corneal abrasion is a Biologic drug developed by Zhongshan Ophthalmic Center, Sun Yat-sen University. It is currently in Phase 1 development.
At a glance
| Generic name | corneal debridement of corneal abrasion |
|---|---|
| Sponsor | Zhongshan Ophthalmic Center, Sun Yat-sen University |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- corneal debridement of corneal abrasion CI brief — competitive landscape report
- corneal debridement of corneal abrasion updates RSS · CI watch RSS
- Zhongshan Ophthalmic Center, Sun Yat-sen University portfolio CI
Frequently asked questions about corneal debridement of corneal abrasion
What is corneal debridement of corneal abrasion?
corneal debridement of corneal abrasion is a Biologic drug developed by Zhongshan Ophthalmic Center, Sun Yat-sen University.
Who makes corneal debridement of corneal abrasion?
corneal debridement of corneal abrasion is developed by Zhongshan Ophthalmic Center, Sun Yat-sen University (see full Zhongshan Ophthalmic Center, Sun Yat-sen University pipeline at /company/zhongshan-ophthalmic-center-sun-yat-sen-university).
What development phase is corneal debridement of corneal abrasion in?
corneal debridement of corneal abrasion is in Phase 1.